Clinical trial
A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8…
NCT00499499 · Eisai Inc., Industry · Suspended
Key facts
| NCT number | NCT00499499 |
|---|---|
| Title | A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors |
| Official title | A Phase I Open-Label, Single-Arm, Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors |
| Lead sponsor | Eisai Inc., Industry |
| Status | Suspended |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | E7107 |
| Enrollment | 40 |
| Start date | Jul 1, 2007 |
| Primary completion | Jun 1, 2009 |
| Completion | Aug 1, 2010 |
| First posted | Jul 11, 2007 |
| Last update posted | Feb 4, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: